{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Soft+Tissue+Metastases&page=3", "query": { "condition": "Soft Tissue Metastases", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 195, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Soft+Tissue+Metastases&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Soft+Tissue+Metastases&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T17:16:56.721Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02298959", "title": "Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Colorectal Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Ovarian Carcinoma", "Metastatic Renal Cell Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Recurrent Melanoma", "Recurrent Renal Cell Carcinoma", "Refractory Melanoma", "Refractory Renal Cell Carcinoma", "Sarcoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Elastography", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ziv-Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2015-04-08", "completion_date": "2027-01-20", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 7, "location_summary": "Tampa, Florida • Bethesda, Maryland • Boston, Massachusetts", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02298959" }, { "nct_id": "NCT04771520", "title": "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Primary Malignant Central Nervous System Neoplasm", "Locally Advanced Sarcoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Primary Malignant Central Nervous System Neoplasm", "Metastatic Sarcoma", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Avapritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2021-01-20", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04771520" }, { "nct_id": "NCT02658487", "title": "Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia With Multilineage Dysplasia", "Myeloid Sarcoma", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Vosaroxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2016-03", "completion_date": "2024-09", "has_results": true, "last_update_posted_date": "2025-04-15", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Charleston, South Carolina • Nashville, Tennessee", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02658487" }, { "nct_id": "NCT00036712", "title": "Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Oral Complications", "Ovarian Cancer", "Pain", "Sarcoma" ], "interventions": [ { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "pain therapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 80, "start_date": "2002-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036712" }, { "nct_id": "NCT02226276", "title": "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bone Metastases", "HER2-positive Breast Cancer", "Liver Metastases", "Lung Metastases", "Recurrent Breast Cancer", "Soft Tissue Metastases", "Stage IV Breast Cancer" ], "interventions": [ { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "copper Cu 64-DOTA-trastuzumab", "type": "RADIATION" }, { "name": "ado-trastuzumab emtansine", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2015-01-07", "completion_date": "2026-09-29", "has_results": true, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02226276" }, { "nct_id": "NCT03604783", "title": "Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Sarcoma", "Ewing Sarcoma", "Dedifferentiated Liposarcoma", "Synovial Sarcoma" ], "interventions": [ { "name": "TP-1287", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 74, "start_date": "2018-12-26", "completion_date": "2024-01-10", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 10, "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT03604783" }, { "nct_id": "NCT04704661", "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Carcinoma", "Advanced Colon Carcinoma", "Advanced Colorectal Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Gastric Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Salivary Gland Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "HER2-Positive Breast Carcinoma", "Malignant Hepatobiliary Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Colon Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Salivary Gland Carcinoma", "Stage III Colon Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Unresectable Breast Carcinoma", "Unresectable Colon Carcinoma", "Unresectable Colorectal Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Carcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Salivary Gland Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2021-08-09", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 23, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 16 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704661" }, { "nct_id": "NCT06349642", "title": "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Early Stage Triple-Negative Breast Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Colorectal Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Skin Neoplasm", "Metastatic Malignant Solid Neoplasm", "Resectable Lung Non-Small Cell Carcinoma", "Early Stage Lung Non-Small Cell Carcinoma", "Resectable Malignant Solid Neoplasm", "Resectable Triple-Negative Breast Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Recurrent Cervical Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Malignant Skin Neoplasm", "Recurrent Malignant Solid Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Tissue Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 324, "start_date": "2024-04-24", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06349642" }, { "nct_id": "NCT02484443", "title": "Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Malignant Neoplasm in the Lung", "Metastatic Osteosarcoma", "Recurrent Osteosarcoma" ], "interventions": [ { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "29 Years", "sex": "ALL", "summary": "Up to 29 Years" }, "enrollment_count": 41, "start_date": "2016-02-04", "completion_date": "2023-09-30", "has_results": true, "last_update_posted_date": "2023-10-26", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 111, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 91 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02484443" }, { "nct_id": "NCT03967223", "title": "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Letetresgene autoleucel (lete-cel, GSK3377794)", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "USWM CT, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 103, "start_date": "2019-12-31", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-23T17:16:56.721Z", "location_count": 24, "location_summary": "Duarte, California • Stanford, California • Denver, Colorado + 19 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03967223" } ] }